145 related articles for article (PubMed ID: 24165906)
1. Pharmacokinetics and pharmacodynamics of tiotropium solution and tiotropium powder in chronic obstructive pulmonary disease.
Hohlfeld JM; Sharma A; van Noord JA; Cornelissen PJ; Derom E; Towse L; Peterkin V; Disse B
J Clin Pharmacol; 2014 Apr; 54(4):405-14. PubMed ID: 24165906
[TBL] [Abstract][Full Text] [Related]
2. The efficacy of tiotropium administered via Respimat Soft Mist Inhaler or HandiHaler in COPD patients.
van Noord JA; Cornelissen PJ; Aumann JL; Platz J; Mueller A; Fogarty C
Respir Med; 2009 Jan; 103(1):22-9. PubMed ID: 19022642
[TBL] [Abstract][Full Text] [Related]
3. Pharmacodynamic steady state of tiotropium in patients with chronic obstructive pulmonary disease.
van Noord JA; Smeets JJ; Custers FL; Korducki L; Cornelissen PJ
Eur Respir J; 2002 Apr; 19(4):639-44. PubMed ID: 11998992
[TBL] [Abstract][Full Text] [Related]
4. [The efficacy and safety of low-dose tiotropium bromide inhaled via Respimat® in patients with chronic obstructive pulmonary disease].
Ma J; Zhou Z; Tang Y; Zhong N
Zhonghua Nei Ke Za Zhi; 2014 Dec; 53(12):964-8. PubMed ID: 25623564
[TBL] [Abstract][Full Text] [Related]
5. Tiotropium 5microg via Respimat and 18microg via HandiHaler; efficacy and safety in Japanese COPD patients.
Ichinose M; Fujimoto T; Fukuchi Y
Respir Med; 2010 Feb; 104(2):228-36. PubMed ID: 19969446
[TBL] [Abstract][Full Text] [Related]
6. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease.
Casaburi R; Mahler DA; Jones PW; Wanner A; San PG; ZuWallack RL; Menjoge SS; Serby CW; Witek T
Eur Respir J; 2002 Feb; 19(2):217-24. PubMed ID: 11866001
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of the efficacy and safety of tiotropium bromide (5 µg) inhaled via Respimat in Chinese patients with chronic obstructive pulmonary disease.
Tang Y; Massey D; Zhong NS
Chin Med J (Engl); 2013; 126(19):3603-7. PubMed ID: 24112149
[TBL] [Abstract][Full Text] [Related]
8. Double-blind randomized parallel group study comparing the efficacy and safety of tiotropium and ipratropium in the treatment of COPD patients in Taiwan.
Hsu JY; Perng RP; Lu JY; Wu CP; Huang MS; Luh KT; Yang PC
J Formos Med Assoc; 2006 Sep; 105(9):708-14. PubMed ID: 16959618
[TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy of dual therapy with GSK233705 and salmeterol versus monotherapy with salmeterol, tiotropium, or placebo in a crossover pilot study in partially reversible COPD patients.
Beier J; van Noord J; Deans A; Brooks J; Maden C; Baggen S; Mehta R; Cahn A
Int J Chron Obstruct Pulmon Dis; 2012; 7():153-64. PubMed ID: 22419863
[TBL] [Abstract][Full Text] [Related]
10. A dose-ranging study of tiotropium delivered via Respimat Soft Mist Inhaler or HandiHaler in COPD patients.
Caillaud D; Le Merre C; Martinat Y; Aguilaniu B; Pavia D
Int J Chron Obstruct Pulmon Dis; 2007; 2(4):559-65. PubMed ID: 18268929
[TBL] [Abstract][Full Text] [Related]
11. Lack of paradoxical bronchoconstriction after administration of tiotropium via Respimat® Soft Mist™ Inhaler in COPD.
Hodder R; Pavia D; Lee A; Bateman E
Int J Chron Obstruct Pulmon Dis; 2011; 6():245-51. PubMed ID: 21814460
[TBL] [Abstract][Full Text] [Related]
12. Tiotropium HandiHaler(®) and Respimat(®) in COPD: a pooled safety analysis.
Halpin DM; Dahl R; Hallmann C; Mueller A; Tashkin D
Int J Chron Obstruct Pulmon Dis; 2015; 10():239-59. PubMed ID: 25709423
[TBL] [Abstract][Full Text] [Related]
13. Tiotropium Respimat inhaler and the risk of death in COPD.
Wise RA; Anzueto A; Cotton D; Dahl R; Devins T; Disse B; Dusser D; Joseph E; Kattenbeck S; Koenen-Bergmann M; Pledger G; Calverley P;
N Engl J Med; 2013 Oct; 369(16):1491-501. PubMed ID: 23992515
[TBL] [Abstract][Full Text] [Related]
14. Tiotropium bromide inhalation powder: a review of its use in the management of chronic obstructive pulmonary disease.
Keating GM
Drugs; 2012 Jan; 72(2):273-300. PubMed ID: 22217233
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of tiotropium Respimat SMI in COPD in two 1-year randomized studies.
Bateman E; Singh D; Smith D; Disse B; Towse L; Massey D; Blatchford J; Pavia D; Hodder R
Int J Chron Obstruct Pulmon Dis; 2010 Aug; 5():197-208. PubMed ID: 20714373
[TBL] [Abstract][Full Text] [Related]
16. In Vitro, Pharmacokinetic, Pharmacodynamic, and Safety Comparisons of Single and Combined Administration of Tiotropium and Salmeterol in COPD Patients Using Different Dry Powder Inhalers.
Horhota ST; van Noord JA; Verkleij CB; Bour LJ; Sharma A; Trunk M; Cornelissen PJ
AAPS J; 2015 Jul; 17(4):871-80. PubMed ID: 25794622
[TBL] [Abstract][Full Text] [Related]
17. A randomized study of tiotropium Respimat Soft Mist inhaler vs. ipratropium pMDI in COPD.
Voshaar T; Lapidus R; Maleki-Yazdi R; Timmer W; Rubin E; Lowe L; Bateman E
Respir Med; 2008 Jan; 102(1):32-41. PubMed ID: 17996436
[TBL] [Abstract][Full Text] [Related]
18. Bronchodilator efficacy of 18 μg once-daily tiotropium inhalation via Discair
Yildiz P; Bayraktaroglu M; Gorgun D; Secik F
Int J Chron Obstruct Pulmon Dis; 2016; 11():2859-2867. PubMed ID: 27920513
[TBL] [Abstract][Full Text] [Related]
19. The spirometric efficacy of once-daily dosing with tiotropium in stable COPD: a 13-week multicenter trial. The US Tiotropium Study Group.
Casaburi R; Briggs DD; Donohue JF; Serby CW; Menjoge SS; Witek TJ
Chest; 2000 Nov; 118(5):1294-302. PubMed ID: 11083677
[TBL] [Abstract][Full Text] [Related]
20. Tiotropium Respimat(®) Versus HandiHaler(®): Comparison of Bronchodilator Efficacy of Various Doses in Clinical Trials.
Calverley PM; Könen-Bergmann M; Richard F; Bell S; Hohlfeld JM
Adv Ther; 2016 May; 33(5):786-93. PubMed ID: 27084728
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
